ClinicalTrials.gg
TerminatedNCT06730282Updated Oct 19, 2026

A Preliminary Study on the Efficacy of Danggui Shaoyao San and Cuscuta Chinensis in Patients With Primary Dysmenorrhea

An interventional study of Danggui Shaoyao San (DSS) and Cuscuta Chinensis (Tu Si Zi) in Primary Dysmenorrhea (PD) and Traditional Chinese Medicine (TCM) Approaches, sponsored by Taichung Tzu Chi Hospital. Terminated at 2 sites in Taiwan. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Taichung Tzu Chi Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
The study was stopped early before reaching the planned enrollment of 200 participants because the allocated research budget was exhausted and additional study medication could not be funded. Enrollment will not resume.
Updated Oct 19, 2026Now TerminatedStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Dysmenorrhea with a site in Taiwan — 4 open to participants now, 6 under way, none of them phase 3. Dysmenorrhea · Taiwan.

Enrollment
Largest of 15
200 · median 60
Started
2025
the only one that year
No phase
12 of 15
3 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Taichung Tzu Chi Hospital

Among the 15 studies in Dysmenorrhea with a site in Taiwan, this one has the largest enrollment, is the only one that started in 2025, is one of 12 with no phase, and was the 12th registered.

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 108 are open to participants now.

Browse Dysmenorrhea studies →

Open to participants now

4 of the 15 studies in Dysmenorrhea with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 59 Dysmenorrhea studies recruiting now, 7 (12%) set no upper age limit and 51 (86%) stop at 75 or younger; 12 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Dysmenorrhea with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of two traditional Chinese medicine (TCM) formulas, Danggui Shaoyao San (DSS) and Cuscuta Chinensis (Tu Si Zi), in treating primary dysmenorrhea (PD). Primary dysmenorrhea, a common condition characterized by painful menstrual cramps, affects many women of reproductive age and significantly impacts their quality of life. Conventional treatments, such as NSAIDs and oral contraceptives, often have limited efficacy or side effects, underscoring the need for alternative therapeutic options.

In this randomized, double-blind study, participants will be divided into four groups: DSS, Tu Si Zi, a combination of DSS and Tu Si Zi, and a placebo group. The study will measure treatment outcomes using the Visual Analogue Scale (VAS) for pain and the Menstrual Symptom Questionnaire (MSQ), which captures physical and emotional symptoms. Additionally, TCM-based tools like pulse diagnosis and constitution questionnaires will be employed to explore personalized treatment strategies.

This research seeks to determine whether these TCM formulas can alleviate pain and improve other menstrual symptoms, potentially providing broader benefits than conventional painkillers. The findings aim to support evidence-based integration of TCM in managing dysmenorrhea and inform clinicians and patients about effective therapeutic choices.

Read the detailed description

Study Overview This study investigates the efficacy of two traditional Chinese medicine (TCM) formulations, Danggui Shaoyao San (DSS) and Cuscuta Chinensis (Tu Si Zi), in managing primary dysmenorrhea (PD). PD is a prevalent condition characterized by painful menstrual cramps, often accompanied by physical and emotional symptoms such as fatigue, irritability, nausea, and breast tenderness. Existing treatment options, including NSAIDs and hormonal contraceptives, are effective for symptom relief but may cause side effects or fail to address associated non-pain symptoms, emphasizing the need for complementary or alternative therapies.

Study Design The trial is a randomized, double-blind, placebo-controlled study. Participants meeting the inclusion criteria will be randomly assigned to one of four groups: DSS, Tu Si Zi, a combination of DSS and Tu Si Zi, or placebo. Each treatment will be administered 3 to 7 days prior to menstruation and continued until 3 days post-menstruation. The intervention spans two consecutive menstrual cycles.

The primary outcomes will be changes in pain intensity measured by the Visual Analogue Scale (VAS) and improvements in menstrual symptoms evaluated using the Menstrual Symptom Questionnaire (MSQ). Secondary outcomes include an exploration of the correlation between TCM pulse diagnosis, TCM constitution types, and therapeutic responses, providing insights into the personalization of treatment based on TCM differentiation (辨證).

Rationale Danggui Shaoyao San, a classic TCM formula, is widely used for blood and qi regulation, reducing uterine contractions, and alleviating menstrual pain. Research suggests that it has anti-inflammatory properties and supports immune regulation, making it suitable for patients with blood stasis and qi stagnation patterns. Conversely, Cuscuta Chinensis, traditionally used to nourish kidney essence and yang, may be effective for individuals with kidney deficiency patterns associated with PD. The combination of these formulas could potentially enhance therapeutic outcomes by addressing multiple pathophysiological mechanisms simultaneously.

Methods Eligible participants are women aged 20-45 years with regular menstrual cycles (21-42 days) and a history of moderate to severe menstrual pain (VAS > 3) persisting for at least three cycles. Participants will be excluded if they have secondary dysmenorrhea caused by underlying conditions (e.g., endometriosis), use intrauterine devices, are pregnant or breastfeeding, or are taking anticoagulants or other conflicting medications.

Participants will undergo the following assessments:

Pain and Symptom Evaluation

VAS: Pain intensity will be measured before, during, and after treatment to assess changes.

MSQ: This tool evaluates menstrual symptoms such as mood changes, fatigue, nausea, diarrhea, and abdominal bloating, offering a comprehensive view of symptom burden.

TCM Diagnostic Tools

Pulse Diagnosis: Using a pulse diagnosis device, data from the radial artery will be collected to assess energy distribution across the pulse positions (cun, guan, chi).

TCM Constitution Questionnaire: Participants will complete a validated questionnaire to determine their constitution type, providing context for their treatment response.

Clinical and Demographic Data Collection

Baseline characteristics, including age, BMI, vital signs, and analgesic use, will be recorded.

Blinding and Randomization Randomization will be performed using a block randomization scheme. All participants, investigators, and outcome assessors will be blinded to group assignments. The study medications, prepared in identical capsules, will be indistinguishable from the placebo. The placebo group will serve as a control to isolate the specific effects of the TCM interventions.

Data Analysis The study will use repeated measures ANOVA to evaluate within-group and between-group differences in VAS and MSQ scores over time. Multivariate linear regression will identify variables influencing treatment outcomes, including constitution type and baseline symptom severity. Statistical significance will be set at p \< 0.05.

Significance and Expected Outcomes This trial aims to determine whether DSS, Tu Si Zi, or their combination can effectively alleviate menstrual pain and associated symptoms, providing a holistic approach to managing PD. Additionally, it seeks to validate the scientific basis of TCM differentiation in treatment selection, enhancing its integration into modern clinical practice. The findings will inform clinicians and patients about effective, personalized therapeutic options and expand the evidence base for TCM in managing gynecological conditions.

Ethical Considerations The study has been approved by the Institutional Review Board (IRB) of Taichung Tzu Chi Hospital. Participants will provide written informed consent before enrollment. All data will be securely stored and anonymized to protect participant privacy.

03

Conditions studied

  • Primary Dysmenorrhea (PD)
  • Traditional Chinese Medicine (TCM) Approaches

Browse trials for

Keywords

  • Primary Dysmenorrhea
  • Traditional Chinese Medicine (TCM)
  • Danggui Shaoyao San (DSS)
  • Cuscuta Chinensis (Tu Si Zi)
  • Herbal Medicine
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants aged 20 to 45 years.
  2. Regular menstrual cycles (21 to 42 days).
  3. History of moderate to severe primary dysmenorrhea (Visual Analogue Scale (VAS) score > 3) persisting for at least three consecutive menstrual cycles.
  4. Able to understand and complete the study questionnaires (e.g., MSQ).
  5. Willing to comply with study protocols, including taking study medications and attending follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Secondary dysmenorrhea caused by conditions such as endometriosis, pelvic inflammatory disease, or uterine fibroids.
  2. Current use of an intrauterine device (IUD).
  3. Irregular menstrual cycles.
  4. Pregnant, breastfeeding, or planning pregnancy within the study period.
  5. Use of anticoagulant medications (e.g., aspirin, warfarin, or heparin).
  6. Known allergies to any components of the study medications.
  7. Severe uncontrolled systemic diseases (e.g., neurological disorders, immunodeficiency, or bleeding disorders).
  8. Concurrent use of other herbal medicines or alternative treatments for premenstrual syndrome or dysmenorrhea.
  9. Participation in another clinical trial during the study period.

    -

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Danggui Shaoyao San

    Participants in this group will receive Danggui Shaoyao San, a traditional Chinese medicine (TCM) formula, for the treatment of primary dysmenorrhea. The medication will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. Danggui Shaoyao San is intended to regulate blood flow, reduce inflammation, and alleviate uterine contractions associated with dysmenorrhea.

    Drug: Danggui Shaoyao San (DSS)

  • Experimental
    Cuscuta Chinensis

    Participants in this group will receive Cuscuta Chinensis, a TCM formula commonly used to support kidney function and alleviate menstrual pain. The medication will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. This group aims to evaluate the efficacy of Cuscuta Chinensis in managing dysmenorrhea symptoms.

    Drug: Cuscuta Chinensis (Tu Si Zi)

  • Experimental
    Danggui Shaoyao San + Cuscuta Chinensis

    articipants in this group will receive a combination of Danggui Shaoyao San and Cuscuta Chinensis. The combined therapy will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. This group aims to assess whether the combination therapy provides enhanced efficacy in reducing pain and other menstrual symptoms compared to single interventions.

    Drug: Combination Therapy (DSS + Tu Si Zi)

  • Placebo comparator
    Placebo

    Participants in this group will receive a placebo that matches the study medications in appearance and packaging. The placebo will be administered starting 3 to 7 days before menstruation and continued until 3 days after menstruation for two consecutive menstrual cycles. This group serves as a control to evaluate the specific effects of the active interventions on primary dysmenorrhea.

    Drug: Placebo

Interventions

  • DrugDanggui Shaoyao San (DSS)

    Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.

  • DrugCuscuta Chinensis (Tu Si Zi)

    Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.

  • DrugCombination Therapy (DSS + Tu Si Zi)

    This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.

  • DrugPlacebo

    Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Measured by the Visual Analogue Scale (VAS)

    Pain intensity will be assessed using the Visual Analogue Scale (VAS), where participants rate their pain on a scale of 0 (no pain) to 10 (worst pain imaginable). The change in scores from baseline to post-treatment will be analyzed to evaluate the interventions' effect on reducing primary dysmenorrhea pain.

    Time frame: Baseline and after two menstrual cycles (approximately 8 weeks)

Secondary outcomes

  1. Change in Menstrual Symptoms Measured by the Menstrual Symptom Questionnaire (MSQ)

    The MSQ evaluates physical and emotional menstrual symptoms, such as irritability, fatigue, abdominal pain, nausea, and breast tenderness. Each symptom is rated on a 5-point Likert scale ("Never" to "Always"). Total and individual scores will be analyzed to assess improvements in symptom burden.

    Time frame: Baseline and after two menstrual cycles (approximately 8 weeks)

  2. Change in the Frequency of Medication Use for Pain Relief

    Participants will report the number of times they used pain medication during each menstrual period at baseline and after two menstrual cycles. In addition, the types and doses of pain medications used will be carefully recorded and analyzed to provide a comprehensive evaluation of treatment efficacy. For statistical analysis, the mean frequency of medication use will be calculated for each participant at baseline and after two menstrual cycles.

    Time frame: Baseline and after two menstrual cycles (approximately 8 weeks)

  3. Correlation Between TCM Pulse Diagnosis Parameters and Menstrual Symptom Severity

    Radial artery pulse data will be collected using a TCM pulse diagnosis device, which measures parameters across three positions: cun, guan, and chi on both the left and right wrists. Each position's waveforms will be analyzed within frequency bands of 0-10Hz, 10-50Hz, and 13-50Hz. Additional parameters, such as SER and EP waveforms, represent distinct characteristics of the radial artery pulse. Pulse data will be correlated with symptom severity, as assessed by the Menstrual Symptom Questionnaire (MSQ), to identify patterns or relationships. This analysis aims to explore how pulse energy distributions and waveform variations reflect changes in symptom intensity and treatment outcomes.

    Time frame: Baseline and after two menstrual cycles (approximately 8 weeks)

  4. Correlation Between TCM Constitution and Treatment Outcomes Using the Body Constitution Questionnaire (BCQ)

    The Body Constitution Questionnaire (BCQ) will be used to assess participants' TCM constitution types, including Yang-deficiency, Yin-deficiency, and Stasis. Participants will rate 44 items on a 5-point scale, reflecting the frequency or severity of symptoms over the past month. The study will analyze correlations between changes in BCQ constitution scores and treatment outcomes, including improvements in pain intensity (VAS) and menstrual symptoms (MSQ), to explore the role of TCM constitution in predicting therapeutic efficacy.

    Time frame: Baseline and after two menstrual cycles (approximately 8 weeks)

Other outcomes

  1. Change in Non-Pain Symptoms of Menstruation

    Non-pain symptoms of menstruation will be assessed using specific items from the Menstrual Symptom Questionnaire (MSQ), including abdominal bloating, nausea, irritability, anxiety, and fatigue. Each symptom is rated on a 5-point Likert scale ranging from "Never" to "Always." For statistical analysis, the mean scores of individual non-pain symptom items will be calculated for each participant at baseline and after two menstrual cycles.

    Time frame: Baseline and after two menstrual cycles (approximately 8 weeks)

07

Study locations

2 sites
  • Taichung Tzu Chi Hospital
    Taichung, Taichung 427, Taiwan
  • Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
    Taichung, 427, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) from this study will be made available to researchers upon reasonable request. The shared data will include all primary and secondary outcome measures as defined in the protocol, along with de-identified demographic and clinical information. Supporting documents, such as the study protocol, statistical analysis plan, and informed consent form, will also be shared to ensure transparency and reproducibility of results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Start Date: Data will be available 6 months after the publication of primary results. End Date: Data will remain accessible for up to 5 years following publication.

Access criteria: Researchers seeking access must submit a written request to the study director, Chung Chia Ying, at jiainwhh@tzuchi.com.tw. Requests must include a detailed research proposal that specifies the intended use of the data and has received approval from an independent ethics review board. Access to the data will require signing a data use agreement, which includes terms to ensure the data are used solely for the proposed purposes and maintained confidentially.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2025 to primary completion in Sep 2026, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Dec 2024 → Feb 2025, primary completion Jun 2026 → Sep 2026 and completion Jun 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2024
First posted
Dec 12, 2024
StartActual
Feb 14, 2025was Dec 2024
Primary completionActual
Sep 12, 2026was Jun 2026
CompletionActual
Sep 12, 2026was Jun 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Terminated The study was stopped early before reaching the planned enrollment of 200 participants because the allocated research budget was exhausted and additional study medication could not be funded. Enrollment will not resume.
changed Oct 19, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 Taiwan)
  • Taichung Tzu Chi Hospital · Taichung, Taiwan
  • Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Taichung, Taiwan
Show 1 removed
  • Taichung Tzu Chi Hospital · Taichung City, Taiwan
Oct 19, 2026
Start date
Dec 1, 2024→Feb 14, 2025 (actual)
Oct 19, 2026
Primary completion
Jun 30, 2026→Sep 12, 2026 (actual)
Oct 19, 2026
Study completion
Jun 30, 2026→Sep 12, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Not yet recruiting→Terminated
    Why stopped The study was stopped early before reaching the planned enrollment of 200 participants because the allocated research budget was exhausted and additional study medication could not be funded. Enrollment will not resume.
    2 sites added, 1 site removed
    Show 2 added (2 Taiwan)
    • Taichung Tzu Chi Hospital · Taichung, Taiwan
    • Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Taichung, Taiwan
    Show 1 removed
    • Taichung Tzu Chi Hospital · Taichung City, Taiwan
    Start date Dec 1, 2024→Feb 14, 2025 (now actual)
    Primary completion Jun 30, 2026→Sep 12, 2026 (now actual)
    Study completion Jun 30, 2026→Sep 12, 2026 (now actual)
    + 6 other changes: identifiers, verification date, oversight details, criteria formatting, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06730282
Lead sponsor
Taichung Tzu Chi Hospital
Responsible party
Chia-Ying Chuang (Attending Physician, Department of Chinese Medicine, Taichung Tzu Chi Hospital, Taichung Tzu Chi Hospital) — Principal investigator
First posted
Dec 12, 2024
Start date
Feb 14, 2025
Primary completion
Sep 12, 2026
Completion
Sep 12, 2026
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion